[Pharmacological and clinical profile of rasburicase (Rasuritek)].
Ohno
Keiji
K
Keiji.Ohno@sanofi-aventis.com
Tawara
Kazuji
K
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D005260:Female; D006074:Gout Suppressants / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D033461:Hyperuricemia / Q000209:etiology* / Q000517:prevention & control*; D007262:Infusions, Intravenous; D008297:Male; D015275:Tumor Lysis Syndrome / Q000209:etiology; D014503:Urate Oxidase / Q000008:administration & dosage* / Q000494:pharmacology*
D000970:Antineoplastic Agents; D006074:Gout Suppressants; C469709:rasburicase; D014503:Urate Oxidase